NASDAQHealth CareHealth Information ServicesSnapshot 2026-07-23
Reading ONMD? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making with volatile management and weak financial performance, which adds to its risk profile.
The market seems to price in a fragile situation, as ONMD has an expensive valuation despite its weak fundamentals. The valuation is higher than peers, suggesting that expectations may not fully account for the ongoing operational challenges.
Management has prioritized addressing compliance issues and improving financial performance, but progress has been limited. Recent revenue sharply declined, and while operating losses improved slightly, the overall financial performance remains weak.
The long-term thesis hinges on the performance of sector bellwethers like VEEV, BTSG, and TEM, as well as potential interest rate cuts by the Fed. Positive momentum in the healthcare sector could provide support, while any negative shifts could impact ONMD significantly.
In the next 1 to 3 years, ONMD's outlook remains uncertain, heavily dependent on external sector factors and internal management execution. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The company is not meeting Nasdaq's $1.00 minimum bid price rule. This could affect its listing status.
Confirms:Nasdaq confirms compliance with the minimum bid price rule.
Disproves:Continued non-compliance with the minimum bid price rule.
Why it matters: A return to higher revenue growth would signal a positive shift in the company's performance.
Confirms:Revenue growth is speeding up again. It is close to 10% year over year.
Disproves:Revenue growth continues to slow or remains below 5% year over year.
Why it matters: Fixing the delisting notice is important. It helps keep investor trust and market access.
Confirms:A press release will confirm compliance with Nasdaq's minimum bid price by August 2026.
Disproves:Failure to regain compliance, leading to a formal delisting from Nasdaq.
Why it matters: Earnings results will show how well the company is doing. This includes its finances and operations.
Confirms one read:The Q2 earnings report shows higher revenue and lower losses than previous quarters.
Confirms the other:Q2 earnings report shows continued losses and no revenue growth.
Why it matters: Revenue fell sharply from $890,000 to $96,000. A recovery would show better finances.
Confirms:Q2 revenue increases above $100,000.
Disproves:Q2 revenue declines further or stays below $96,000.
Why it matters: This agreement allows the company to raise up to $25 million. It could help improve financial stability.
Confirms:The company says it sold equity under the agreement. This was a success.
Disproves:The company does not complete the equity sale or cancels the agreement.
